Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]

Eur Urol. 2025 Jan;87(1):96. doi: 10.1016/j.eururo.2024.10.002. Epub 2024 Oct 18.

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mkscc.org.

No abstract available

Publication types